Tailoring Treatment in Metastatic Melanoma for Best Outcomes

Tailoring Treatment in Metastatic Melanoma for Best Outcomes

A Case-Based Educational Series: Case Two of Two

View Activity

Activity Features

CME Certified

Opinion Poll

prIME eCases

View Activity

Provider

This activity is provided by prIME Oncology.

Activity Date

RELEASE DATE
February 15, 2018

EXPIRATION DATE
February 15, 2019

Case Two Review

Your patient is a 77-year-old woman with melanoma who has become symptomatic with fatigue over the past 3 weeks. She has multiple small subcutaneous nodules on her buttocks and back that she had not noticed; however, you are able to palpate them, and she can feel a couple of things on her chest and legs that have come up over the past week. She swears that nothing was there 2 weeks ago.

The patient’s LDH level is 1300 U/L (normal for your lab is up to 650 U/L). MRI of the brain shows no lesions, but on CT scan you find she has multiple liver metastases, small bony metastases, and multiple lung metastases. She also has a nodule in her spleen. The patient is quite fatigued and her performance status is 1. You see in her prior physician notes that she has had stage III resected disease in her left axilla and she is BRAF mutation–positive, V600K.

 

To view Case One, please click here.

Activity Overview

prIME Oncology virtual melanoma eCases deliver concise interactive clinical scenarios along with data to support different decision points along the patient’s disease course. Each case covers different aspects of the treatment of patients with metastatic melanoma.

Faculty

  • Jeffrey S. Weber, MD, PhDLaura and Isaac Perlmutter Cancer Center
    NYU Langone Medical Center
    New York, New York, United States

Target Audience

The activity is designed to meet the needs of medical oncologists, nurse practitioners, physician assistants, nurses, and other healthcare professionals who treat and/or manage patients with melanoma.

Learning Objectives

After successful completion of this educational activity, participants should be able to:

  • Identify recent changes to the TNM staging system in melanoma, as it relates to the management of high-risk resected and metastatic disease
  • Implement optimal treatment strategies for metastatic melanoma based on patient- and disease-related factors
  • Develop management strategies to ameliorate the adverse effects associated with systemic therapies used in the treatment of metastatic melanoma

Support

This educational activity is supported by a grant from Novartis Oncology.

CME and Disclosure Information

Release Date

February 15, 2018

Expiration Date

February 15, 2019

Faculty

  • Jeffrey S. Weber, MD, PhD
    Laura and Isaac Perlmutter Cancer Center
    NYU Langone Medical Center
    New York, New York, United States

Learning Objectives

After successful completion of this educational activity, participants should be able to:

  • Identify recent changes to the TNM staging system in melanoma, as it relates to the management of high-risk resected and metastatic disease
  • Implement optimal treatment strategies for metastatic melanoma based on patient- and disease-related factors
  • Develop management strategies to ameliorate the adverse effects associated with systemic therapies used in the treatment of metastatic melanoma

Provider

This activity is provided by prIME Oncology.

Support

This educational activity is supported by a grant from Novartis Oncology.

Target Audience

The activity is designed to meet the needs of medical oncologists, nurse practitioners, physician assistants, nurses, and other healthcare professionals who treat and/or manage patients with melanoma.

Continuing Medical Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

ACCME-commendation-full-color

prIME Oncology designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online posttest and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database. However, upon request, your CME credit certificate will be emailed to you. Technical requirements may be found under the Terms of Use.

Links to the posttest are available at the end of the activity.

In order to receive credit, participants must successfully complete the online posttest with 75% or higher.

Disclosures

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Weber has disclosed that he has received consulting fees from Altor, Astra Zeneca, Biond, Bristol-Myers Squibb, Celldex, CytoMx, Genentech, GSK, Merck, Novartis, and Windmil. He was an independent contractor for clinical research with AstraZeneca, Bristol-Myers Squibb, Genentech, GSK, Incyte, Merck, and Novartis. He also has a patent for a CTLA-4 biomarker by Morgh and for a PD-1 biomarker by Biodesix. He is a member on advisory committees or review panels for Altor, CytoMx, Celldex, and Windmil. He also has ownership interest in Alter, Biond, Celldex, and CytoMx. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

  • Ronald Viggiani, MD (medical director content reviewer/planner) – no relevant financial relationships
  • Elizabeth Cameron, PhD (scientific content reviewer/planner) – no relevant financial relationships
  • Jessica Mastrodomenico, MPH (editorial content reviewer) – no relevant financial relationships